NASA and Singularity U Partner to Create SynBio Launchpad

In a first of its kind, a new incubator modeled on the well known Y Combinator has been started for emerging synthetic biology companies. SynBio Launchpad is a joint effort by Singularity University, provider of higher education in exponentially advancing industries, and their landlord, NASA. The program came about from a discussion between Andrew Hessel, co-chair of SU’s Biotechnology and Bioinformatics track, and John Cumbers, Deputy Managing Director of Synthetic Biology at NASA.

At the Center of the Bioinformatics Universe with Atul Butte

This podcast originally aired on April 3, 2012

Podcast Sponsor: Audacity - Building health and science brand supremacy through disruptive marketing and advertising. Download "4 Secrets to Brand Supremacy," for free


Atul Butte, MD,PhD, Associate Professor of Pediatrics, Medicine, and Computer Science, Stanford Bio and Contact Info

Listen (0:58) How did you get to the center of the bioinformatics universe?

Listen (2:06) 99% of our work is coming up with great questions

Listen (1:59) When will we have a new molecular based classification for disease?

Listen (2:54) What are you most passionate about?

Listen (3:45) iPOP - Integrated Personal Omics Profiling

Listen (2:07) Biggest challenge to clinical sequencing

Listen (1:57) Bioinformatician - the new hybrid

Listen (6:05) Thoughts on entrepreneurship

Listen (2:22) The dry researcher

Listen (3:32) Looking ahead

As part of our series, 'Finding Meaning in the Data,' we’re pleased to have Dr. Atul Butte to the program. He is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics, Medicine, and Computer Science, at Stanford University and Lucile Packard Children's Hospital. The Butte Lab at Stanford has received a good amount of press as one of the leading labs worldwide focused on converting billions of molecular and clinical data into meaningful new insights into disease. Atul trained in Computer Science and received an MD at Brown University, worked as a software engineer at Apple and Microsoft, trained in Pediatrics at Children's Hospital Boston, then received his PhD in Health Sciences and Technology from Harvard Medical School and MIT. He’s the co-founder and scientific advisor to several start-ups, including NuMedii and Personalis.

Investing at the Intersections with Rowan Chapman, Mohr Davidow

Podcast Sponsor: Chempetitive Group - Adding "life" to life science marketing


Rowan Chapman, Mohr Davidow Bio and Contact Info

Listen (3:35) I've got a PhD, what next?

Listen (5:38) How did you become an investor?

Listen (6:14) Mohr Davidow investing in industry intersections

Listen (3:58) What can you tell start-ups about approaching VC?

Listen (4:17) Trends in life science funding

Listen (4:20) What hot spots excite you today?

Rowan Chapman is a partner at the VC firm, Mohr Davidow, and first dedicated member of the team devoted to life science. Rowan says she has a passion to work with entrepreneurs in a "hands on" role to help get companies started and financed. She’s a board member of four companies including Sequenta, VitaPath Genetics, and Health Tap and a board observer at Cardio Dx and Tethys Bioscience. Prior to that she worked closely with the board for PacBio, Paralelle, and RainDance. She has her finger on things all the way from tools, to social media, to diagnostics, to therapeutics. She is also a member of the Personalized Medicine Coalition. Prior to joining Mohr Davidow, Rowan held the position of director of business development at Rosetta Inpharmatics (acquired by Merck) We’re very happy to have her join us to talk about the investment side of the industry.